| Abstrakt: |
This article discusses a newly launched clinical trial, NCT06474533, which focuses on the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET is a substance that accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and determine the grade of glial neoplasms. The trial aims to differentiate between benign treatment-related changes and recurrence in patients with metastatic disease and high-grade gliomas, as well as differentiate between low-grade and high-grade gliomas. Participants will undergo a PET scan after receiving an injection of FET, and their clinical outcomes will be assessed. The study is open to individuals of all genders aged 4 years and above and is regulated by the U.S. FDA. [Extracted from the article] |
